Article of all potential future cures Treatment 5/2/2025
Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.
View this post in the Community →
Similar Community Posts Join
3 / 4 resultscommunity Update July 2025] Most Promising Hair Loss Treatments in Clinical Trials
Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.
community How do we only have two treatments to combat hair loss at this point in time?
The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.
community Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?
A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.
Related Research
6 / 252 results
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Hydrogel Forming Microneedles Loaded With VEGF and Ritlecitinib/Polyhydroxyalkanoates Nanoparticles for Mini-Invasive Androgenetic Alopecia Treatment
New microneedle treatment with growth factors and a hair loss drug shows better and faster hair growth results than current treatments.
research The FDA Approves Litfulo® (Ritlecitinib) for the Treatment of Severe Alopecia Areata in Adolescents and Adults
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Research Progress in the Treatment of Non-Scarring Alopecia: Mechanism and Treatment
New treatments are needed for non-scarring alopecia due to current limitations.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.